Decentralizing kidney care.

Team

Tom Weindl

CEO & Co-Founder

Nir Nativ

CTO

Ray Luo

Chief Data & Strategy Officer

OLI

Company details

There are nearly 1 million end-stage kidney patients in the US. And while going to the hospital or center for dialysis is an inconvenience and major disruption to their daily lives, only 1 in 50 patients currently opt for in-home dialysis. This is because current options for in-home dialysis are unpleasant and impractical to use. They are large and obtrusive, they force patients to be stuck in their homes for extended periods, and they are very complex to operate. Oli is building a better future for these patients, by creating compact, portable, and intuitively operated dialysis systems, so that these patients can get their lives back again. Oli’s core technology has been developed around a novel sorbent that enables this huge step forward in miniaturization and simplified operation. They will begin initial deployment of their MVP in clinic, in order to accelerate regulatory approval for patient use in-home or on-the-go.

Get In Touch with OLI

Please tell us a little bit about yourself and why you'd like to get connected. OLI + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
Opt-in checkbox


We don’t spam. Our Privacy Policy and Terms of Use apply.
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More